(Q37762545)

22 August 2017

1 reference

title

Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. (English)

1 reference

22 August 2017

1 reference

1 reference

James Fung

1

0 references

Ching-Lung Lai

object named as

Ching-Lung Lai

series ordinal

2

0 references

author name string

Man-Fung Yuen

series ordinal

3

1 reference

22 August 2017

language of work or name

1 reference

1 June 2010

1 reference

Expert Review of Anti-infective Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

8

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

717-726

1 reference

Hepatitis B virus infection--natural history and clinical consequences

22 August 2017

cites work

1 reference

The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points.

21 January 2018

1 reference

Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection

21 January 2018

1 reference

The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study.

21 January 2018

1 reference

An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

21 January 2018

1 reference

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B and C virus-related carcinogenesis.

21 January 2018

1 reference

The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence

21 January 2018

1 reference

Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection.

21 January 2018

1 reference

Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks

21 January 2018

1 reference

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

21 January 2018

1 reference

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

Prevention and management of drug resistance for antihepatitis B treatment

21 January 2018

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

21 January 2018

1 reference

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

21 January 2018

1 reference

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

21 January 2018

1 reference

Determinants for sustained HBeAg response to lamivudine therapy

21 January 2018

1 reference

The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion.

21 January 2018

1 reference

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

Preferential ribosomal scanning is involved in the differential synthesis of the hepatitis B viral surface antigens from subgenomic transcripts

21 January 2018

1 reference

Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment

21 January 2018

1 reference

Hepatitis B small surface antigen particles are octahedral

21 January 2018

1 reference

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay

21 January 2018

1 reference

Hepatitis B e antigen and the risk of hepatocellular carcinoma

21 January 2018

1 reference

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years.

21 January 2018

1 reference

HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma.

21 January 2018

1 reference

Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges

21 January 2018

1 reference

Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy

21 January 2018

1 reference

Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

21 January 2018

1 reference

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

21 January 2018

1 reference

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

21 January 2018

1 reference

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.

21 January 2018

1 reference

Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression

21 January 2018

1 reference

Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-α-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B

21 January 2018

1 reference

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

21 January 2018

1 reference

Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERI.10.45

1 reference

22 August 2017

1 reference